Oct 2026
Targeting Distinct Cell Cycle Nodes Overcomes RAS Inhibitor Resistance.
Activating mutations in KRAS drive pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Although mutant-selective KRAS inhibitors and pan-RAS inhibitors provide clinical benefits, the development of resistance limits durable responses. Here, transcriptomic and proteomic analyses revealed that...
V. Kumarasamy, Jian-Xin Wang, Edwin H. Yau et al.
· Cancer Research · 0 citations